. | . |
Preliminary results positive for Moderna mRNA flu vaccine by AFP Staff Writers Washington (AFP) Dec 10, 2021 US biotech company Moderna on Friday announced promising data from an early-stage human trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine. The experimental flu shot was found to be safe, and successfully evoked high levels of antibodies in 180 people at all dosage levels, in both younger and older adults. "Even before the Covid-19 pandemic, approximately three million people died each year due to respiratory infections, and many more are hospitalized or become ill as a result of these viruses," said Moderna CEO Stephane Bancel in a statement hailing the result. Side effects were mild, and occurred more often in younger than older adults. The most common included pain and tenderness at the injection site, as well as headaches, muscle and joint aches, and tiredness. The next stage of the trial, involving 500 people, began last month, and aims to firm up the right dosage level and compare the Moderna flu vaccine to already-licensed shots developed using more traditional methods. Interim results are expected in early 2022. Later stages of the trial will assess the vaccine's efficacy. The majority of current flu vaccines are based on inactivated viruses cultivated in chicken eggs. Virus strains have to be selected six to nine months before the vaccines are intended to be used, and their efficacy is approximately 40 to 60 percent. Moderna and other vaccine manufacturers, including Sanofi, hope that mRNA technology -- which provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells -- can accelerate immunization development and production, and heighten efficacy. Several mRNA molecules that encode for different strains can also be delivered in the same shot, a more efficient vaccination method that could lessen the load on public health systems. Moderna's experimental flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization. The company is also developing other flu shots that expand strain coverage further still, including a "pan-respiratory booster" to cover Covid-19, flu, and respiratory syncytial virus (RSV), a common virus that causes the cold but can be more serious for infants and elderly people.
Hong Kong mandates Covid tracing app for most adults in bars, restaurants Hong Kong (AFP) Dec 9, 2021 The Hong Kong government made its check-in app mandatory for most adults in bars and restaurants on Thursday, the latest expansion of coronavirus tracing tech at a time of heightened privacy concerns in the city. The international finance hub has kept infections at bay thanks to mostly closed borders, some of the world's strictest quarantine rules and ongoing social distancing rules. No local infections have been recorded in months, but the city is further ramping up virus measures, aligning wi ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |